Atara Biotherapeutics (ATRA) Operating Leases (2022 - 2025)
Historic Operating Leases for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $15.0 million.
- Atara Biotherapeutics' Operating Leases fell 5742.42% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 5742.42%. This contributed to the annual value of $29.9 million for FY2024, which is 3453.26% down from last year.
- As of Q3 2025, Atara Biotherapeutics' Operating Leases stood at $15.0 million, which was down 5742.42% from $15.4 million recorded in Q2 2025.
- Over the past 5 years, Atara Biotherapeutics' Operating Leases peaked at $64.0 million during Q2 2022, and registered a low of $15.0 million during Q3 2025.
- For the 4-year period, Atara Biotherapeutics' Operating Leases averaged around $40.3 million, with its median value being $42.2 million (2024).
- In the last 5 years, Atara Biotherapeutics' Operating Leases surged by 21466.22% in 2023 and then tumbled by 6014.26% in 2025.
- Atara Biotherapeutics' Operating Leases (Quarter) stood at $58.1 million in 2022, then fell by 21.31% to $45.7 million in 2023, then plummeted by 34.53% to $29.9 million in 2024, then tumbled by 49.84% to $15.0 million in 2025.
- Its Operating Leases was $15.0 million in Q3 2025, compared to $15.4 million in Q2 2025 and $26.7 million in Q1 2025.